Abstract:Lu Li, 1 Lin Li, 1 Xianhui Cai, 1 Zongfu Pan 2 1 Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China; 2 Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, People's Republic of China Correspondence: Zongfu Pan, Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China, Email Coronavirus disease 2019 (COVID-19)-induced new-onset diabetes has raised widespread concerns. Increased glucose concentration and insulin resistance levels were observed in the COVID-19 patients. COVID-19 patients with newly diagnosed diabetes may have worse clinical outcomes and can have serious consequences. The types and exact mechanisms of COVID-19-caused diabetes are not well understood. Understanding the direct effects of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on pancreatic beta cells and insulin target metabolism organs, such as the liver, muscle, and adipose tissues, will provide new ideas for preventing and treating the new-onset diabetes induced by COVID-19. Keywords: COVID-19, SARS-CoV-2, new-onset diabetes, hyperglycemia Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To date, COVID-19 has infected more than 774 million people and caused 7.01 million deaths. 1 There is a bidirectional relationship between COVID-19 and diabetes. 2 It is well known that diabetes increases the risk of severe COVID-19. On the other hand, SARS-CoV-2 infections have been associated with increased rates of new-onset diabetes, and the diabetic effects may persist even after infection recovery. 3–7 The new-onset hyperglycemia caused by COVID-19 may result in long-term hyperglycemia, worse clinical outcomes, prolonged hospital stays, and a greater need for oxygen support or positive pressure ventilation. 4 COVID-19 patients with newly diagnosed diabetes had higher a risk of all-cause mortality compared with COVID-19 patients with known diabetes and normal glucose. 8,9 Laurenzi et al found that the prevalence of glycemic abnormalities returned to the preadmission frequency when the SARS-CoV-2 infection diminished and speculated that diabetes caused by COVID-19 was not likely to become a lasting public health problem. 10 However, the available evidence has shown that such a possibility exists and needs to be alerted and investigated. Although the infection can cause stress hyperglycemia, the available data suggests that stress hyperglycemia alone does not explain the new-onset diabetes caused by COVID-19. COVID-19 may have a diabetogenic effect independent of the stress response during a severe disease. Type 1 diabetes and type 2 diabetes are the most prevalent types of diabetes. They are different from their pathologic characteristics. The incidence of patients with type 1 or type 2 diabetes cases increased following the COVID-19 pandemic. 11 It appears that exposure to SARS-CoV-2 precipitates the onset of type 1 diabetes. 12 In patients with COVID-19 and those recovering from COVID-19, fasting insulin, C-peptide levels, homeostasis model assessment of β cell dysfunction (HOMA-β) and homeostasis model assessment of insulin resistance (HOMA-IR) level were higher, 4,13 indicating multiple effects of SARS-CoV-2 infection on insulin-secreting organs as well as insulin-targeting organs. These phenomena suggested that new-onset diabetes may be different from type 1 diabetes. A retrospective cohort analysis found that COVID-19 increased the risk of type 2 diabetes, while the incidence rates of other types of diabetes did not increase. 14 Genetic correlation and detection of Mendelian randomization showed a bidirectional causal relationship between type 2 diabetes and SARS-CoV-2 infections. 15 New-onset diabetes caused by COVID-19 might not simply be classified as type 1 or type 2 diabetes in terms of symptoms and mechanisms because of the atypical glycemic parameters. 16 The virus-induced β cell cytotoxicity, insulin resistance and immune dysfunction were assumed to contribute to new-onset diabetes. 17 Here, we conducted a narrative review using an open search strategy on PubMed with the search terms (("COVID-19" [Mesh]) OR "SARS-CoV-2" [Mesh]) AND ("Diabetes Mellitus" [Mesh]). We filtered the researches focusing on the effects of SARS-CoV-2 on metabolic organs, including -Abstract Truncated-

[An economic perspective on targeted treatments].

Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments.

SARS-CoV-2 disrupts proximal elements in the JAK-STAT pathway

Type 2 Diabetes Contributes to Altered Adaptive Immune Responses and Vascular Inflammation in Patients With SARS-CoV-2 Infection

Inflammation and Antiviral Immune Response Associated With Severe Progression of COVID-19

SARS-CoV-2 in the pancreas and the impaired islet function in COVID-19 patients

COVID-19 induces new-onset insulin resistance and lipid metabolic dysregulation via regulation of secreted metabolic factors

SARS-CoV-2 Infection Aggravates Chronic Comorbidities of Cardiovascular Diseases and Diabetes in Mice.

Infection with SARS-CoV-2 can cause pancreatic impairment

SARS-CoV-2 desensitizes host cells to interferon through inhibition of the JAK-STAT pathway

An insight into the mechanisms of COVID-19, SARS-CoV2 infection severity concerning β-cell survival and cardiovascular conditions in diabetic patients

SARS-CoV-2 infection drives an inflammatory response in human adipose tissue through infection of adipocytes and macrophages

Anti-infection effects of heparin on SARS-CoV-2 in a diabetic mouse model

Designs for the Most Vulnerable of Patients

Interaction of Severe Acute Respiratory Syndrome Coronavirus 2 and Diabetes

Cardiovascular Risk After SARS-CoV-2 Infection Is Mediated by IL18/IL18R1/HIF-1 Signaling Pathway Axis

New Insights into the Effects of SARS-CoV-2 on Metabolic Organs: A Narrative Review of COVID-19 Induced Diabetes

Metabolic reprogramming and epigenetic changes of vital organs in SARS-CoV-2–induced systemic toxicity

Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy

SARS-CoV-2 infection induces beta cell transdifferentiation

Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning